---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002728"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:47:22.811747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx amends debt facility to $100M, draws $10M; Q4 rev ~$16M (+4-5% YoY)

## Summary
- Debt facility increased by $50M to $100M; $10M drawn at closing, total outstanding $60M; maturity extended to May 2031.
- Q4 2025 preliminary revenue $15.9-16.1M (+4-5% YoY); full-year 2025 revenue $56.5-56.7M (+10-11% YoY).
- FY2026 guidance: revenue $63-67M (+11-18% YoY); gross margin 84-86%; operating expenses $103-107M.
- BENEFIT-HF trial: FDA IDE granted Nov 2025; applied for CMS coverage; net trial costs $20-30M over 5-7 years.
- Cash and equivalents $75.7M as of Dec 31, 2025; 252 active implanting centers; 53 sales territories.

## SEC filing metadata
- accession: 0001104659-26-002728
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/tm262733d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002728
- JSON: https://secwatch.observer/filing/0001104659-26-002728.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002728.txt

## Key facts
- Debt Financings
  CVRx, Inc. incurred term loan of $10 million with Innovatus Life Sciences Fund I, LP at prime rate plus 2.65% maturing May 9, 2031.
  - Instrument: term loan
  - Principal: $10 million
  - Counterparty: Innovatus Life Sciences Fund I, LP
  - Rate: prime rate plus 2.65%
  - Maturity: May 9, 2031
  - Event: incurrence
  source text: revenue exceeds $100 million. The term loans continue to be secured by substantially all of the Company’s assets. Also on the Closing Date, the Company borrowed an additional $10 million under the Loan Agreement, bringing the total outstanding principal amount of term loans to $60 million. The Company has the option to draw (i) $15 million between June 1, 2027
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm
- Debt Financings
  CVRx, Inc. amended credit facility of $50 million with Innovatus Life Sciences Fund I, LP at floating rate per annum equal to the sum of (i) the greater of (A) the prime rat maturing May 9, 2031.
  - Instrument: credit facility
  - Principal: $50 million
  - Counterparty: Innovatus Life Sciences Fund I, LP
  - Rate: floating rate per annum equal to the sum of (i) the greater of (A) the prime rat
  - Maturity: May 9, 2031
  - Event: amendment
  source text: Pursuant to the Amendment, (a) the terms loans available to the Company are increased by $50 million, to an aggregate principal amount of up to $100 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm
- Material Agreements
  CVRx, Inc. amended Amendment with Innovatus Life Sciences Fund I, LP valued at $50 million (effective 2026-01-09).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Innovatus Life Sciences Fund I, LP
  - Value: $50 million
  - Effective: 2026-01-09
  source text: On January 9, 2026 (the “Closing Date”), CVRx, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its existing Loan and Security Agreement dated October 31, 2022, as previously amended on March 13, 2023 (as amended, the “Loan Agreement”), among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.